Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Presentation Author(s):

Xenofon Baraliakos¹ , Mikkel Østergaard² , Denis Poddubnyy³ , Désirée van der Heijde⁴ , Atul Deodhar⁵ , Pedro M. Machado⁶ , Victoria Navarro-Compán⁷ , Kay Geert Hermann⁸ , Mitsumasa Kishimoto⁹ , Eun Young Lee¹⁰, Lianne S. Gensler¹¹, Uta Kiltz¹ , Marco F. Eigenmann¹², Patricia Pertel¹², Aimee Readie¹³, Hanno B. Richards¹², Brian Porter¹³, Juergen Braun¹

¹ Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Germany; ² Center for Rheumatology and Spine Diseases, Center of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark; ³ Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany; ⁴ Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; ⁵ Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, USA; ⁶ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK; ⁷ Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain; ⁸ Department of Radiology, University Hospital Charité - Campus Mitte, Berlin, Germany; ⁹ Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; ¹¹Department of Medicine, Division of Rheumatology, University of California, San Francisco, California, USA; ¹²Novartis Pharma AG, Basel, Switzerland; ¹³Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Abstract or description:

Audio narration provided by Dr. Atul Deodhar M.D.